Back to top
more

Zogenix, Inc. (ZGNX)

(Delayed Data from NSDQ)

$38.02 USD

38.02
750,722

-0.18 (-0.47%)

Updated May 3, 2019 04:00 PM ET

After-Market: $38.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Zogenix (ZGNX) Reports Q4 Loss, Tops Revenue Estimates

Zogenix (ZGNX) delivered earnings and revenue surprises of -8.89% and 1.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zogenix (ZGNX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: ZGNX's Acquisition News, REGN, BLUE's Updates & More

Regulatory and other pipeline updates from Zogenix (ZGNX) and Regeneron (REGN) are among a few key highlights from the biotech sector during the past week.

Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB

Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.

Zogenix (ZGNX) Stock Jumps 65.7%: Will It Continue to Soar?

Zogenix (ZGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zogenix (ZGNX) Reports Q3 Loss, Tops Revenue Estimates

Zogenix (ZGNX) delivered earnings and revenue surprises of -8.33% and 0.49%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zogenix (ZGNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zogenix (ZGNX) Moves 6.2% Higher: Will This Strength Last?

Zogenix (ZGNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zogenix (ZGNX) Reports Q2 Loss, Tops Revenue Estimates

Zogenix (ZGNX) delivered earnings and revenue surprises of -12.90% and 10.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zogenix (ZGNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zogenix (ZGNX) Reports Q1 Loss, Tops Revenue Estimates

Zogenix (ZGNX) delivered earnings and revenue surprises of -2.04% and 9.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Zogenix (ZGNX) to Report a Decline in Earnings: What to Look Out for

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zogenix (ZGNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zogenix (ZGNX) Reports Q3 Loss, Tops Revenue Estimates

Zogenix (ZGNX) delivered earnings and revenue surprises of -0.99% and 50.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Zogenix (ZGNX)

Zogenix (ZGNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zogenix (ZGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zogenix (ZGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zogenix (ZGNX) Reports Q2 Loss, Misses Revenue Estimates

Zogenix (ZGNX) delivered earnings and revenue surprises of 5.88% and -6.18%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Zogenix (ZGNX) Q2 Earnings Expected to Decline

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zogenix (ZGNX) in Focus: Stock Moves 7.6% Higher

Zogenix (ZGNX) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline developments.

Zogenix Gets FDA Nod for Dravet Syndrome Seizure Treatment

Zogenix (ZGNX) gets FDA nod for Fintepla oral solution, CIV for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age or older.

Are Options Traders Betting on a Big Move in Zogenix (ZGNX) Stock?

Investors need to pay close attention to Zogenix (ZGNX) stock based on the movements in the options market lately.

Zogenix (ZGNX) Reports Q1 Loss, Tops Revenue Estimates

Zogenix (ZGNX) delivered earnings and revenue surprises of 35.19% and 24.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Zogenix (ZGNX) This Earnings Season?

Zogenix (ZGNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

How Zogenix (ZGNX) Stock Stands Out in a Strong Industry

Zogenix (ZGNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.